Yi-ming Sun

State Key Laboratory Of Drug Research
Shanghai, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

HDAC inhibitor GCJ-490A modulates tumor microenvironment and synergizes with PD-1 antibody against breast and lung cancers in syngeneic murine models.

HDAC inhibitor GCJ-490A modulates tumor microenvironment and synergizes with PD-1 antibody against breast and lung cancers in syngeneic murine models.

Journal: Acta pharmacologica Sinica

Published: March 31, 2025

Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.

Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.

Journal: European journal of medicinal chemistry

Published: June 05, 2023

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.

Journal: EMBO molecular medicine

Published: April 29, 2022

SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.

SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.

Journal: Acta pharmacologica Sinica

Published: December 22, 2020

DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo.

DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo.

Journal: Acta pharmacologica Sinica

Published: May 08, 2020

Author Correction: AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.

Author Correction: AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.

Journal: Acta pharmacologica Sinica

Published: February 16, 2020

EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.

EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.

Journal: Haematologica

Published: March 26, 2019

AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.

AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.

Journal: Acta pharmacologica Sinica

Published: March 06, 2019

Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer.

Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer.

Journal: Cancer letters

Published: March 30, 2018

Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.

Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.

Journal: Acta pharmacologica Sinica

Published: December 27, 2016

Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer.

Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer.

Journal: Theranostics

Published: October 06, 2016

Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.

Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.

Journal: Cancer letters

Published: September 15, 2016

Showing 1-12 of 14

Last Updated: 09/26/2026